SCHEMBL6690888

SCHEMBL6690888

NC(=O)c1cccc2c1c1c(O)cccc1n2Cc1cccc2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CMA1 P23946 1/20 0.46
MCL1 Q07820 6/20 0.46
BAD Q92934 6/20 0.46
PLA2G2A P14555 2/20 0.45
PLA2G1B P04054 1/20 0.45
KDM4E B2RXH2 3/20 0.44
F10 P00742 1/20 0.43
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
AURKB Q96GD4 1/20 0.43
MAPK8 P45983 1/20 0.43
CD38 P28907 1/20 0.42
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31511324 0.89 MEN1 (0.50) MEN1KMT2ACMA1MCL1BAD
SCHEMBL7425661 0.89 MEN1 (0.50) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6781636 0.88 MCL1 (0.45) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6775459 0.88 MCL1 (0.48) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6776083 0.86 PLA2G1B (0.42) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6690168 0.86 MAPK8 (0.53) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6775683 0.85 PLA2G1B (0.41) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6776015 0.84 MCL1 (0.44) MEN1KMT2ACMA1MCL1BAD
SCHEMBL6691170 0.84 PLA2G2A (0.46) MEN1KMT2APLA2G2AKDM4EAURKA
SCHEMBL6774411 0.84 AURKA (0.41) MEN1KMT2APLA2G2AKDM4EAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed